A 33% confirmed objective response rate in heavily pretreated patients sounds modest until you consider what it took to get there: an all-oral dual PI3K/mTOR blockade stacked on top of paclitaxel, in a population where the median patient had already failed two prior lines of therapy. Faeth Therapeutics filed an 8-K on November 9 disclosing positive preliminary Phase 2 topline results from the PIK-201 trial, which tested PIKTOR, a combination of the PI3K-alpha inhibitor serabelisib and the mTORC1/2 inhibitor sapanisertib, alongside paclitaxel in patients with advanced endometrial cancer carrying a PI3K/AKT/mTOR pathway mutation.
The confirmed ORR of 33% in that pretreated, biomarker-selected group carries weight in context. Phase 1 data had suggested a strong early signal in a small evaluable endometrial cancer cohort. Phase 2 pulls that number back to earth, but 33% confirmed responses in patients who had already cycled through a median of two prior regimens, including likely exposure to the checkpoint inhibitors now embedded in first-line regimens for this disease, still represents a clinically meaningful signal for a fully oral backbone.
The design choice worth noting is the biomarker gate. Restricting enrollment to PAM-pathway-mutated tumors trades accrual speed for a cleaner biological hypothesis: that dual-node suppression of PI3K and mTOR is more likely to produce durable responses when the pathway is actually activated by an underlying mutation. Endometrial cancer carries some of the highest rates of PI3K pathway alterations of any solid tumor, so the eligible population is not trivially small. The paclitaxel combination adds a chemotherapy partner without converting PIKTOR into an intravenous regimen, which matters for patient logistics in the relapsed setting.
The filing attaches the full press release as Exhibit 99.1 but The 8-K filing itself, beyond attaching the press release, does not separately summarize progression-free or overall survival data, duration of response, or registrational-study plans. Those gaps are the ones to close: a confirmed ORR in this pretreated biomarker-selected cohort gets Faeth to the table for a pivotal conversation with regulators, but the durability data will determine whether that conversation produces a trial design worth running.
Source link: https://www.sec.gov/Archives/edgar/data/1829802/000119312526452643/d199028d8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
